Research Topic

Neoadjuvant and Adjuvant Management of Gastric Cancer

  • Submission closed.

About this Research Topic

Background: As the fifth most frequently diagnosed cancer and third leading cause of cancer death worldwide, gastric cancer accounts for 5.7% of new cases and 8.2% of total deaths, with 1,033,701 new cases and 782,685 deaths in 2018. Complete surgical resection currently is the basic treatment for ...

Background: As the fifth most frequently diagnosed cancer and third leading cause of cancer death worldwide, gastric cancer accounts for 5.7% of new cases and 8.2% of total deaths, with 1,033,701 new cases and 782,685 deaths in 2018. Complete surgical resection currently is the basic treatment for localized stomach cancer. However, gastric cancer is often diagnosed at an advanced stage that is unsuitable for radical surgery. Even despite potentially curative surgical resections, the prognosis of patients with more advanced gastric cancer remains poor due to metastatic disease or local recurrence after radical surgical resection. The high risk of disease relapse prompted the investigation of multimodal treatments that include neoadjuvant and adjuvant treatments.

Previous clinical trials have assessed the outcomes of preoperative, postoperative and perioperative treatments, producing conflicting results and established the efficacy of several treatments. For example, postoperative chemotherapy including XELOX and S-1 and postoperative chemoradiotherapy for gastric cancer are recommended in several guidelines. Perioperative FLOT has been recommended for gastric cancer in NCCN guideline. More recently, CRITICS-study demonstrated that postoperative chemoradiotherapy did not improve OS as compared to postoperative chemotherapy after adequate preoperative CT and surgery. With the increasing publications in this area, new evidence for the efficacy and safety of different multidisciplinary strategies is constantly developing.

Scope: The goal of this Research Topic is to present the latest advances in new evidence of multidisciplinary strategies including preoperative, postoperative and perioperative treatments for gastric cancer.

Details for Authors: This Research Topic will include studies on new advances and management of neoadjuvant and adjuvant treatments for gastric cancer. Topic Editors welcome manuscripts of the following types: Original Research articles, Reviews or Mini-Reviews, Opinions, or meta-analyses focusing on:

- Efficacy and safety of new and old multidisciplinary strategies including preoperative, postoperative and perioperative treatments for gastric cancer. Treatments can include chemotherapy and chemoradiotherapy.
- Identification of new biomarkers related to the outcomes of patients treated with neoadjuvant or adjuvant chemotherapy.


We hope that this Research Topic will inspire communication among researchers and open up new research perspectives in the study of neoadjuvant or adjuvant treatments for gastric cancer.


Keywords: gastric cancer, neoadjuvant, adjuvant, chemotherapy, chemoradiotherapy


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Recent Articles

Loading..

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

Submission closed.

Participating Journals

Loading..

Topic Editors

Loading..

Submission Deadlines

Submission closed.

Participating Journals

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..